Health ❯ Obesity

Weight Loss

Medications Pharmaceuticals Pharmaceutical Treatments Medication Bariatric Surgery GLP-1 Drugs Clinical Trials Surgery GLP-1 Medications Medical Treatments Dietary Interventions Treatment Options Weight Loss Drugs Clinical Studies Fitness Programs Treatment Methods Interventions Pharmaceutical Innovations Pharmacology Semaglutide Treatment Strategies Injections Dietary Phases Brain Activity Brain-Gut Microbiome Interplay Intermittent Energy Restriction Metagenomics Physiological Parameters Obesity-related Comorbidities Appetite-Suppressants Drug Comparison Effects of Tirzepatide Exercise Impact Drug Trials Weight Loss Medications Weight Loss Journey Medication Efficacy Appetite Suppressants Dietary Supplements Side Effects Comorbidities Gastric Bypass Alternatives Anti-obesity Drugs Factors Influencing Weight Loss Men's Health Psychological Effects Off-label Drug Use Pharmaceutical Alternatives Dietary Education Drug Efficacy Diet Quality Improvement Medication Adherence Weight Maintenance Wegovy Fitness Journey Weight Management Weight Loss Surgery Mental Health Drug Development Weight Loss Treatments Medicines Fitness Physical Health Personal Struggles Appetite Regulation Mental Challenges Biological Responses Research Patient Care Dietary Changes Weight Loss Camps Health Complications Surgical Interventions Clinical Outcomes Medical Conditions Medication Access Thermogenesis Caloric Expenditure Treatment Side Effects GLP-1 RAs Pharmaceutical Drugs Text Messages Research Trials Behavioral Economics Research Studies Caloric Restriction Prescription Medications Mounjaro Rybelsus, Danuglipron, Orforglipron Drug Treatments Medical Devices Gastric Balloons Artificial Sweeteners Personal Transformation Lifestyle Changes Diet Companies Diet, Exercise Body Weight Reduction Calorie-Deficit Diet Misperceptions about Disease Management

Zealand Plunges as Roche Obesity Drug Posts 10.7% Weight Loss With Placebo‑Like Tolerability

Underwhelming efficacy has investors questioning differentiation, dose response, Phase 3 upside.

Novo’s Triple-Hormone Obesity Drug UBT251 Hits 19.7% Mean Weight Loss in China Phase 2

Eli Lilly Builds $1.5 Billion Stockpile of Orforglipron as FDA Decision Nears

WHO-Backed Reviews Affirm GLP-1 Weight-Loss Gains as Clinicians Flag Safety and Nutrition Gaps

GLP-1 Weight-Loss Boom Triggers Safety Warnings and New Oversight

‘My 600-lb Life’ Alum Charity Pierce Dies at 50

Roche’s CT-388 Shows Up to 22.5% Placebo-Adjusted Weight Loss in Phase 2 as Phase 3 Nears

Oprah Winfrey Recasts Obesity as Disease in New Book, Backs GLP-1s as Long-Term Care

Weight Returns Quickly After Stopping GLP-1 Drugs, Oxford Review Finds

EMA Panel Backs Higher 7.2 mg Wegovy Dose for Obesity

WHO Endorses GLP‑1s for Obesity as Australia Adds Class‑Wide Mental Health Warning

Eli Lilly Becomes First Health Care Company Valued at $1 Trillion

GLP-1 Drugs Linked to Lower Five-Year Death Risk in Colon Cancer, UCSD Study Finds

White House Finalizes GLP-1 Price Deal With Lilly and Novo, Setting $50 Medicare Copays

U.S. Strikes Price-Cut Deals With Novo Nordisk and Eli Lilly for GLP‑1s, With Medicare Pilot in 2026

U.S. Obesity Rate Drops to 37% as GLP-1 Use Surges, Gallup Finds

Pilot Study Ties GLP-1 Drugs to Slower Alcohol Absorption and Milder Intoxication

BMJ Retracts Apple Cider Vinegar Weight-Loss Study After Errors and Data Irregularities

Monthly Phone Coaching Sustains Weight Loss for 20 Months as Algorithmic Extra Calls Fall Short

Lilly’s Orforglipron Pill Hits Phase 3 Goals and Outperforms Oral Semaglutide in Diabetes Study